Wednesday, July 8, 2026

Drug profile · INN

felbamate

felbamate (FELBAMATE) is a glutamate [nmda] receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — felbamate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

felbamate (FELBAMATE) is a glutamate [nmda] receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN felbamate
Brand FELBAMATE
Mechanism Glutamate [NMDA] receptor antagonist
Target Glutamate [NMDA] receptor
Route ORAL
Formulation SUSPENSION

Mechanism of action

Glutamate [NMDA] receptor antagonist

Primary target: Glutamate [NMDA] receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amantadine hydrochloride Glutamate [NMDA] receptor antagonist
  2. memantine hydrochloride Nervous system (N06)
  3. esketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator
  4. ketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator
  5. orphenadrine citrate Norepinephrine transporter inhibitor
  6. orphenadrine hydrochloride Norepinephrine transporter inhibitor

Frequently asked questions

What is felbamate?

felbamate (FELBAMATE) is a glutamate [nmda] receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for felbamate?

FELBAMATE is a marketed brand name for felbamate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of felbamate?

felbamate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.